LivaNova PLC (NASDAQ:LIVN) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. decreased its position in LivaNova PLC (NASDAQ:LIVN) by 34.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 11,376 shares of the company’s stock after selling 6,023 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in LivaNova were worth $598,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its position in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after acquiring an additional 370 shares during the period. Lazard Asset Management LLC acquired a new position in LivaNova in the 1st quarter valued at $84,000. Canada Pension Plan Investment Board purchased a new position in shares of LivaNova during the 2nd quarter worth $88,000. Finally, Central Pacific Bank Trust Division acquired a new stake in shares of LivaNova during the third quarter worth $178,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

LivaNova stock opened at $52.48 on Friday. The firm has a fifty day moving average of $52.24 and a 200-day moving average of $52.30. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.85 billion, a P/E ratio of 124.95 and a beta of 1.01.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Mizuho dropped their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Monday. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Robert W. Baird increased their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, LivaNova currently has a consensus rating of “Buy” and a consensus price target of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.